Peptide therapy claims on TikTok: what the science actually supports

What did @amierhaidarmd actually say?

He pushed back hard on a specific rationalization: that peptides are fine to use because the COVID-19 vaccine also lacked research. His counter was that mRNA vaccine research had decades of foundation behind it. Then he made a broader argument: most peptides people are actually injecting themselves with have "hardly any human data" for safety or efficacy, and the problem gets worse when people stack them without medical supervision.

He drew a meaningful line between peptides with substantial human data, like GLP-1 agonists, and those like GHK-Cu where essentially all we have are topical studies. He did not tell people to stop at all costs. He said if you are going to use peptides, work with a physician who can monitor you.

Does the science back this up?

Largely, yes. The mRNA vaccine history he described is accurate, and the peptide data gap he identified is real. Where things get more complicated is his implicit grouping of approved drugs like semaglutide alongside research compounds under the broad label of "peptides."

On mRNA: Katalin Karikó and colleagues published foundational work on modified mRNA as early as 2005 (Karikó et al., 2005, Immunity). The rabies mRNA vaccine he mentioned was tested in a Phase I trial reported by Alberer et al. (2017, The Lancet), with earlier groundwork in animal models beginning around 2013. His timeline is slightly compressed but directionally correct.

On GHK-Cu: A 2015 review by Pickart and Margolina in the journal Cosmetics confirmed that the overwhelming majority of GHK-Cu research is in vitro or animal-based, with topical formulations accounting for virtually all human exposure data. There is no published human clinical trial on injected GHK-Cu as of early 2025. His point here is well-supported.

On GLP-1 receptor agonists: These are FDA-approved drugs with extensive Phase II and III trial data. Lumping them with unregulated research peptides is a bit misleading, even if technically accurate to call them peptides.

What did they get wrong (or right)?

He got the core argument right. The COVID-19 vaccine comparison used to justify peptide use is a false equivalence, and he correctly dismantled it. That talking point circulates constantly in biohacking communities and deserves pushback.

What he got slightly wrong, or at least imprecise, is the framing of GLP-1s alongside compounds like GHK-Cu and TB-500. Semaglutide and tirzepatide have undergone thousands of patient-hours of clinical trial scrutiny. Calling them peers of research peptides muddies the water. The distinction between an FDA-approved drug and an unscheduled research compound is not a technicality. It is the entire ballgame for informed consent and risk assessment.

He also mentioned "Epitide" and "RETA" without much context. These appear to be emerging compounds with limited but growing clinical data, and lumping them into the "more data available" category without qualification could give listeners a false sense of security about compounds most physicians have never prescribed.

His recommendation to work with a monitoring physician is reasonable and responsible. It does not fix the absence of safety data, but it is a better harm-reduction approach than unsupervised self-injection based on forum posts.

What should you actually know?

The peptide market is operating well ahead of the evidence. That is not a scare tactic. It is what the published record actually shows. A 2023 systematic review by Lau et al. in Frontiers in Pharmacology found that for most research peptides marketed for recovery and anti-aging, human clinical trial data is either absent or limited to small Phase I safety signals, not efficacy outcomes.

Stacking peptides, which means combining multiple compounds simultaneously, compounds the problem. Drug-drug interactions are identified through controlled studies. When you combine compounds that have never been tested together in humans, you are generating your own uncontrolled experiment. There is no safety database tracking outcomes for people who combine BPC-157 with TB-500 and a growth hormone secretagogue simultaneously.

Physician supervision helps, but only if the physician has access to validated reference ranges and monitoring protocols. For most research peptides, those do not exist. A physician can order labs, but interpreting what "normal" looks like on GHK-Cu injections is not something current evidence supports.

If you are interested in peptide therapy, ask your provider specifically which compounds have peer-reviewed Phase II or III human data for your intended use case. The answer will narrow the list considerably.